Molecular characterization of diabetic heart of akita
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA277353 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:To understand the molecular profile of diabetic heart in animal model of type 1 diabeties Akita, we performed RNA sequencing of heart tissue (male) at the 12 week to understand systemic changes.
2015-09-30 | GSE66576 | GEO
Project description:To understand the molecular profile of diabetic heart in animal model of type 1 diabeties Akita, we performed RNA sequencing of heart tissue (male) at the 12 week to understand systemic changes.
2015-09-30 | GSE66575 | GEO
Project description:Molecular characterization of diabetic heart of akita (array)
| PRJNA277354 | ENA
Project description:Molecular characterization of diabetic heart of akita (RNA-Seq)
| PRJNA277355 | ENA
Project description:Increased morbidity and mortality associated with post-ischemic heart failure (HF) in diabetic patients underscore the need for a better understanding of the underlying molecular events. Indeed, effective HF therapy in diabetic patients requires a complex strategy encompassing the development of improved diagnostic and prognostic markers and innovative pharmacological approaches. Whole mRNAs expression was measured in the heart of patients with heart failure (HF) with or without concomitant Type 2 diabetes mellitus (T2DM) and compared it to control non-failing hearts. We identified distinct genes modulated in HF patients compared to controls, as well as to T2DM HF patients compared to not diabetic HF patients. Our study included left ventricle (LV) cardiac biopsies taken from the vital, non-infarcted zone (remote zone) derived from patients affected by dilated hypokinetic post-ischemic cardiomyopathy, undergoing surgical ventricular restoration procedure. Inclusion criteria for diabetic were: GLICEMIA: >=126 mg/dl, previous T2DM diagnosis or anti-diabetic therapy, while for non diabetic: GLICEMIA: <100 mg/dl and HbA1c: n.v. 4.8-6.0%. Moreover, HF patients were matched for End Systolic Volume (ESV), Ejection fraction (LVEF), Age, Sex, Ethnic distribution, Smoke habits, Hypertension, Glomerular filtration rate (GFR), Body Mass Index (BMI). Genes expression was assessed by Affymetrix GeneChips Human Gene 1.0 ST array, using total RNA extracted from 7 T2DM HF patients, 12 non-T2DM HF patients and 5 controls.
2012-03-21 | E-GEOD-26887 | biostudies-arrayexpress
Project description:Increased morbidity and mortality associated with post-ischemic heart failure (HF) in diabetic patients underscore the need for a better understanding of the underlying molecular events. Indeed, effective HF therapy in diabetic patients requires a complex strategy encompassing the development of improved diagnostic and prognostic markers and innovative pharmacological approaches. Whole mRNAs expression was measured in the heart of patients with heart failure (HF) with or without concomitant Type 2 diabetes mellitus (T2DM) and compared it to control non-failing hearts. We identified distinct genes modulated in HF patients compared to controls, as well as to T2DM HF patients compared to not diabetic HF patients.
2012-03-21 | GSE26887 | GEO
Project description:Congenital heart defects (CHD) are one of the most common defects in offspring of diabetic mothers. There is a clear association between maternal diabetes and CHD; however the underlying molecular mechanism remains unknown. We hypothesized that maternal diabetes affects with the expression of early developmental genes that regulate the essential developmental processes of the heart, thereby resulting in the pathogenesis of CHD. We analyzed genome-wide expression profiling in the developing heart of embryos from diabetic and control mice by using the oligonucleotide microarray. Microarray analysis revealed that a total of 878 genes exhibited more than 1.5 fold changes in expression level in the hearts of experimental embryos in either E13.5 or E15.5 compared with their respective controls. Expression pattern of genes that is differentially expressed in the developing heart was further examined by the real-time reverse transcriptase-polymerase chain reaction. Several genes involved in a number of molecular signaling pathways such as apoptosis, proliferation, migration and differentiation in the developing heart were differentially expressed in embryos of diabetic pregnancy. It is concluded that altered expression of several genes involved in heart development may contribute to CHD in offspring of diabetic mothers.
2011-09-14 | GSE32078 | GEO
Project description:Maternal diabetes causes cardiac malformations in fetuses. In this study, we have analyzed the differential gene expression profiling in the developing heart of embryos from diabetic and control mice by using the oligonucleotide microarray. Expression patterns of genes and proteins that are differentially expressed in the developing heart were further examined by the real-time reverse transcriptase-polymerase chain reaction and immunohistochemistry. Embryos of diabetic pregnancies displayed cardiac malformations. Microarray analysis revealed the genes that were altered in expression level in the developing heart of embryos from diabetic mice when compared to controls. It is concluded that altered expression of a variety of genes involved in heart development is associated with cardiac malformations in offsprings of diabetic mother. We used microarrays to identify the genes specific to the developing heart of embryos from control and diabetic mice RNA was isolated from heart tissue of control and diabetes exposed E13.5 and E15.5 mouse embryos (three samples each). The RNA was hybridised onto Affymetrix Mouse Genome 430 2.0 Array.
2011-09-13 | E-GEOD-32078 | biostudies-arrayexpress
Project description:The type 2 diabetes medication, rosiglitazone, has come under scrutiny for possibly increasing the risk of cardiac disease and death. To investigate the effects of rosiglitazone on the diabetic heart, we performed cardiac transcriptional profiling of a murine model of type 2 diabetes, the C57BL/KLS-leprdb/leprdb (db/db) mouse. We compared cardiac gene expression profiles from three groups: untreated db/db mice (db-c), db/db mice after rosiglitazone treatment (db-t), and non-diabetic db/+ mice. Mice were divided into three groups: Non-diabetic controls (db/+), untreated diabetic controls (db-c), and rosiglitazone-treated diabetic mice (db-t). Whole-heart RNA from five mice from each of the three groups after four months with or without treatment was used for microarray analysis.Universal Reference RNAs for mouse (Stratagene, La Jolla, CA) were purchased as microarray reference controls.
2012-03-28 | E-GEOD-36875 | biostudies-arrayexpress
Project description:Molecular characterization of DLBCL
| PRJNA605794 | ENA